Bryn Mawr Capital Management LLC Sells 114,338 Shares of Johnson & Johnson (NYSE:JNJ)

Bryn Mawr Capital Management LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 86.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,016 shares of the company’s stock after selling 114,338 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Johnson & Johnson were worth $2,605,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Private Advisor Group LLC grew its stake in shares of Johnson & Johnson by 69.1% during the fourth quarter. Private Advisor Group LLC now owns 435,449 shares of the company’s stock valued at $62,975,000 after buying an additional 177,879 shares during the last quarter. Keene & Associates Inc. boosted its holdings in Johnson & Johnson by 5.9% during the 4th quarter. Keene & Associates Inc. now owns 20,328 shares of the company’s stock valued at $2,940,000 after acquiring an additional 1,134 shares during the period. Financial Perspectives Inc grew its position in Johnson & Johnson by 3.9% in the 4th quarter. Financial Perspectives Inc now owns 8,106 shares of the company’s stock valued at $1,172,000 after acquiring an additional 305 shares during the last quarter. Alberta Investment Management Corp increased its stake in Johnson & Johnson by 770.6% in the fourth quarter. Alberta Investment Management Corp now owns 127,976 shares of the company’s stock worth $18,508,000 after purchasing an additional 113,276 shares during the period. Finally, Summit Place Financial Advisors LLC lifted its position in shares of Johnson & Johnson by 0.5% during the fourth quarter. Summit Place Financial Advisors LLC now owns 18,248 shares of the company’s stock worth $2,639,000 after purchasing an additional 90 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.7 %

NYSE JNJ opened at $162.35 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a 50 day moving average price of $148.93 and a 200 day moving average price of $155.88. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market cap of $390.87 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.29 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Ratings Changes

Several research firms recently commented on JNJ. Wells Fargo & Company reduced their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Barclays raised their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 28th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Stifel Nicolaus reduced their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Activity

In related news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.